Treatment of acute pyelonephritis in children: Author's reply

BMJ

Volumn 328, Issue 7445, 2004, Pages 957-

  Craig, Jonathan C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CEFIXIME; CEFOTAXIME;

ACUTE PYELONEPHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CHILD; CICATRIX; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; PYELONEPHRITIS;

EID: 1942446235     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.328.7445.957-a     Document Type: Letter

References (3)

1. Stokland E, Hellstrom M, Jacobsson B, Jodal U, Sixt R. Evaluation of DMSA scintigraphy and urography in assessing both acute and permanent renal damage in children. Acta Radiologica 1998; 39: 447–52.
2. Craig JC, Irwig LM, Knight JF, Roy LP. Does treatment of vesicoureteric reflux in childhood prevent end-stage renal disease attributable to reflux nephropathy? Pediatrics 2000; 105: 1236–41.
3. Craig JC, Irwig L, Ford M, Willis NS, Howman-Giles RB, Uren RF, et al. Reliability of DMSA for the diagnosis of renal parenchymal abnormality in children. Eur J Nuclear Med 2000; 27: 1610–6.